Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer

Published:2014-07-17 Issue:6b Volume:114 Page:E25-E31
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Sonpavde Guru¹,Pond Gregory R.²,Armstrong Andrew J.³,Galsky Matthew D.⁴,Leopold Lance⁵,Wood Brian A.⁵,Wang Shaw-Ling⁶⁷,Paolini Jolanda⁶,Chen Isan⁶⁸,Chow-Maneval Edna⁶⁸,Mooney David J.¹,Lechuga Mariajose⁶,Smith Matthew R.⁹,Michaelson M. Dror⁹

Affiliation:

1. Department of Medicine; Division of Hematology-Oncology; University of Alabama; Birmingham (UAB) Comprehensive Cancer Center; Birmingham AL USA

2. Department of Biostatistics; McMaster University; Hamilton ON Canada

3. Department of Medicine; Division of Hematology-Oncology; Duke Prostate Center; Durham NC USA

4. Department of Medicine; Division of Hematology-Oncology; Mt Sinai Tisch Cancer Institute; New York NY USA

5. Ascenta Therapeutics; Malvern PA USA

6. Pfizer Inc.; Madison NJ USA

7. ICON Clinical Research Inc.; San Diego CA USA

8. Seragon Pharmaceuticals; San Diego CA USA

9. Department of Medicine; Division of Hematology-Oncology; Massachusetts General Hospital and the Harvard Medical School; Boston MA USA

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12589/fullpdf

Reference22 articles.

1. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16;Petrylak;J Natl Cancer Inst,2006

2. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer;Armstrong;J Clin Oncol,2007

3. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916;Hussain;J Clin Oncol,2009

4. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy;Sonpavde;Cancer,2011

5. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer;Halabi;J Clin Oncol,2009

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy;Seminars in Nuclear Medicine;2024-01

2. Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus Without Confirmatory Bone Scan;Cancer Research and Treatment;2023-12-05

3. Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients;Clinical Genitourinary Cancer;2022-02

4. Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials;Pharmaceuticals;2022-01-26

5. Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply;The Lancet Oncology;2022-01